RxDoctor Payments Data

Fouad Batah, MD

Internal Medicine · Southfield, MINPI 1285618983

Payments from drug & device makers

$19,644in general payments, 2019–2025

Across 1,111 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • GSK$2K
  • Lilly USA, LLC$2K
  • Amgen$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $10K from 53 others

What the payments were for

  • Food & beverage$19,610100%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk126$2,185
AstraZeneca(2 entities)110$1,911
GSK100$1,589
Lilly USA, LLC114$1,564
Amgen48$1,503
Teva Pharmaceuticals USA, Inc.75$1,248
Pfizer51$861
Johnson & Johnson(2 entities)65$835
AbbVie(2 entities)45$803
Sanofi-aventis U.S. LLC34$756
Merck47$701
Amarin Pharma, Inc.27$491
Xeris Pharmaceuticals, Inc.23$457
Novartis27$439
Abbott16$347
Dexcom, Inc.17$312
Otsuka America Pharmaceutical, Inc.5$297
Boehringer Ingelheim14$268
Exact Sciences12$253
Bayer13$249
UCB, Inc.14$215
Esperion Therapeutics, Inc.5$197
Astellas Pharma US Inc12$185
E.r. Squibb & Sons, L.L.C.13$178
Lundbeck LLC7$160
Shield Therapeutics Inc9$154
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$108
Biohaven Pharmaceutical Holding Company Ltd.5$104
Acadia Pharmaceuticals Inc6$91
Ironwood Pharmaceuticals, Inc5$90
Takeda Pharmaceuticals U.S.A., Inc.4$82
Sanofi Pasteur Inc.4$80
Vanda Pharmaceuticals Inc.3$77
Gilead4$75
Daiichi Sankyo Inc.5$68
Scilex Pharmaceuticals Inc.3$65
Abiomed3$48
Actelion Pharmaceuticals US, Inc.3$47
Biogen2$43
Corcept Therapeutics2$42
Sumitomo Pharma America, Inc.2$39
BD2$37
Kowa Pharmaceuticals America, Inc.3$37
Insmed, Inc.2$36
Avanir Pharmaceuticals, Inc.2$33
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$31
Pulmonx Corporation1$26
Amphastar Pharmaceuticals, Inc.1$24
Sunovion Pharmaceuticals Inc.1$21
Axsome Therapeutics, Inc.1$21
Boston Scientific1$20
Neurocrine Biosciences, Inc.1$19
Mallinckrodt Hospital Products Inc.1$19
Electromed, Inc.2$18
Sanofi1$18
Endo Pharmaceuticals Inc.1$17
Ultragenyx Pharmaceutical Inc.1$17
Biohaven Pharmaceuticals, Inc.1$15
Circassia Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,644 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$215,063
Medicare patients
363
Services billed
2,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin217$208,735
EliquisApixaban201$186,562
FarxigaDapagliflozin Propanediol150$146,968
OzempicSemaglutide115$131,436
Trelegy ElliptaFluticasone/Umeclidin/Vilanter163$116,676
MounjaroTirzepatide70$83,921
TrulicityDulaglutide47$77,621
EntrestoSacubitril/Valsartan63$70,638
XareltoRivaroxaban51$65,707
JanuviaSitagliptin Phosphate25$34,392
MyrbetriqMirabegron23$24,271
RybelsusSemaglutide17$24,126
Breo ElliptaFluticasone/Vilanterol56$22,798
Synjardy XrEmpagliflozin/Metformin Hcl22$18,171
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$17,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$268$226,906239 claims
PfizerEliquis$861$186,562201 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,911$164,015177 claims
Lilly USA, LLCMounjaro, Trulicity$1,564$161,542117 claims
Novo NordiskOzempic, Rybelsus$2,185$155,562132 claims
GSKTrelegy Ellipta, Breo Ellipta$1,589$139,474219 claims
NovartisEntresto$439$70,63863 claims
Johnson & JohnsonXarelto$835$65,70751 claims
MerckJanuvia, Janumet$701$50,15236 claims
Astellas Pharma US IncMyrbetriq$185$24,27123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →